<p>Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.  Related Content:</p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.27022?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years</a></li> </ul>

Azithromycin to Prevent Childhood Mortality in Sub-Saharan Africa

Interviews with leading researchers and thinkers in health care about practice-changing research, innovations, and the most pressing issues facing medicine and health care today from JAMA, the Journal of the American Medical Association.